<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00983619</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP204</org_study_id>
    <nct_id>NCT00983619</nct_id>
  </id_info>
  <brief_title>A Clinical Study Using MEDI-551 in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies</brief_title>
  <official_title>A Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose of this drug (MEDI-551)
      in subjects with advanced B-cell malignancies. Expansion to occur at maximum tolerated dose
      (MTD), or if not reached, at optimal biologic dose (OBD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the maximum tolerated dose (MTD) or optimal biologic dose (OBD) of MEDI-551 in
      subjects with relapsed or refractory advanced B-cell malignancies.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 16, 2010</start_date>
  <completion_date type="Anticipated">December 28, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 28, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the MTD or highest protocol defined dose of MEDI-551 in subjects with relapsed or refractory advanced B-cell malignancies and to determine the preliminary safety profile in these populations.</measure>
    <time_frame>Study Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of MEDI-551 in subjects with advanced B-cell malignancies, and to characterize the PK and effect on circulating lymphocyte populations and Ig levels, and the immunogenicity of MEDI-551.</measure>
    <time_frame>30 days after last dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>B-cell Malignancies</condition>
  <arm_group>
    <arm_group_label>Dose Escalation: Cohort 1 (FL/MM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are dosed with Dose level 1 of active drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation: Cohort 2 (FL/MM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be dosed with Dose level 2 of active drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Esc: Cohort 3 (FL/MM/CLL/DLBCL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be dosed with dose level 3 of active drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation: Cohort 4 (CLL/DLBCL/FL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be dosed with dose level 4 of active drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Esc: Cohort 5 (FL/MM/CLL/DLBCL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be dosed with dose level 5 of active drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Esc: Cohort 6 (FL/MM/CLL/DLBCL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be dosed with dose level 6 of active drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: Cohort 7 (FL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be dosed with MTD or OBD determined for FL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: Cohort 8 (CLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be dosed with MTD or OBD determined for CLL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: Cohort 9 (DLBCL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be dosed with MTD or OBD determined for DLBCL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation: Cohort 10 (CLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be dosed with Dose Level 1 of active drug for CLL dose escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation: Cohort 11 (CLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be dosed with Dose Level 2 of active drug for CLL dose escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: Cohort 12 (CLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be dosed with Dose Level 3 of active drug for CLL dose escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: Cohort 13 (CLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be dosed with Dose Level 4 of active drug for CLL dose escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: Cohort 14 (CLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be dosed based on the MTD identified in the dose escalation CLL phase (Cohorts 10-13)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Esc: Cohort 15 (Agressive Lymphoma)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are dosed with dose level 1 of active drug and 375 mg/m2 of rituximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Esc: Cohort 16 (Agressive Lymphoma)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are dosed with dose level 2 of active drug and 375 mg/m2 of rituximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Exp: Cohort 17 (Agressive Lymphoma)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are dosed with MTD identified in the dose escalation phase (Cohorts 15-16) and 375 mg/m2 of rituximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>anti-CD20 Refract Aggressive Lymphoma Cohort 18</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be dosed based on MTD identified in dose escalation (Cohorts 1-6)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-551</intervention_name>
    <description>A humanized Immunoglobulin G (IgG)1 kappa monoclonal antibody (MAb) directed against human CD19.</description>
    <arm_group_label>Dose Escalation: Cohort 1 (FL/MM)</arm_group_label>
    <arm_group_label>Dose Escalation: Cohort 2 (FL/MM)</arm_group_label>
    <arm_group_label>Dose Esc: Cohort 3 (FL/MM/CLL/DLBCL)</arm_group_label>
    <arm_group_label>Dose Escalation: Cohort 4 (CLL/DLBCL/FL)</arm_group_label>
    <arm_group_label>Dose Esc: Cohort 5 (FL/MM/CLL/DLBCL)</arm_group_label>
    <arm_group_label>Dose Esc: Cohort 6 (FL/MM/CLL/DLBCL)</arm_group_label>
    <arm_group_label>Dose Expansion: Cohort 7 (FL)</arm_group_label>
    <arm_group_label>Dose Expansion: Cohort 8 (CLL)</arm_group_label>
    <arm_group_label>Dose Expansion: Cohort 9 (DLBCL)</arm_group_label>
    <arm_group_label>Dose Escalation: Cohort 10 (CLL)</arm_group_label>
    <arm_group_label>Dose Escalation: Cohort 11 (CLL)</arm_group_label>
    <arm_group_label>Dose Expansion: Cohort 12 (CLL)</arm_group_label>
    <arm_group_label>Dose Expansion: Cohort 13 (CLL)</arm_group_label>
    <arm_group_label>Dose Expansion: Cohort 14 (CLL)</arm_group_label>
    <arm_group_label>Dose Esc: Cohort 15 (Agressive Lymphoma)</arm_group_label>
    <arm_group_label>Dose Esc: Cohort 16 (Agressive Lymphoma)</arm_group_label>
    <arm_group_label>Dose Exp: Cohort 17 (Agressive Lymphoma)</arm_group_label>
    <arm_group_label>anti-CD20 Refract Aggressive Lymphoma Cohort 18</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Anti CD-20 and MEDI-551</description>
    <arm_group_label>Dose Esc: Cohort 15 (Agressive Lymphoma)</arm_group_label>
    <arm_group_label>Dose Esc: Cohort 16 (Agressive Lymphoma)</arm_group_label>
    <arm_group_label>Dose Exp: Cohort 17 (Agressive Lymphoma)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women at least 18 years of age or older at time of study entry

          2. Written informed consent and HIPAA authorization (applies to covered entities in the
             USA only) obtained from the subject/legal representative prior to performing any
             protocol-related procedures, including screening evaluations

          3. Diagnosis Arm A: CLL (including SLL), DLBCL, or FL; SLL, DLBCL, and FL must be
             histologically confirmed Arm B: Histologically confirmed SLL or previous confirmation
             of B-cell CLL with a characteristic immunophenotype by flow cytometry Arm C:
             Histologically confirmed aggressive B-cell DLBCL, including FL transforming to DLBCL,
             transformed indolent lymphoma, MCL, or Grade 3b FL, according to the World Health
             Organization (WHO)/American Joint Committee on Cancer (AJCC) criteria Arm D:
             Histologically confirmed anti-CD20-refractory (defined as any subject with less than a
             PR to any prior anti-CD20-based therapy or progression within 6 months after
             completing therapy with any anti-CD20-based regimen, including maintenance rituximab)
             aggressive B-cell DLBCL, including FL transforming to DLBCL, transformed indolent
             lymphoma, MCL, or Grade 3b FL, according to the WHO/AJCC criteria

          4. Optional: Willing to provide a fresh tumor sample if a sufficient quantity of archival
             tumor sample is not available (Arms B, C, and D). See Section 5.3.9 for tumor sample
             details.

          5. Evaluable/measurable disease

             Non-CLL B-cell malignancies (Arms A, C, and D):

               -  Histologically confirmed B-cell NHL (FL or DLBCL), transformed indolent lymphoma,
                  and MCL: Measurable disease defined as ≥ 1 lesion ≥ 20 mm in one dimension or ≥15
                  mm in 2 dimensions as measured by conventional or high-resolution (spiral)
                  computed tomography (CT). For Arms C and D: disease evaluable by the
                  International Working Group criteria (Cheson et al, 2007)

               -  Baseline PET or PET/CT scans must show positive lesions compatible with
                  CT-defined anatomical tumor sites (only applicable for FL, DLBCL, MCL,
                  transformed indolent lymphoma, and FL transforming to DLBCL)

             CLL (Arms A and B):

               -  Confirmed B-cell CLL/SLL with a characteristic immunophenotype by flow cytometry,
                  and symptomatic disease requiring treatment

               -  CT scans showing involvement of ≥ 1clearly demarcated lesions measuring ≥ 1.5 cm

          6. Prior therapy

               -  Arm A:

                    -  Histologically confirmed B-cell NHL (FL or DLBCL): Relapsed from or
                       refractory to ≥ 1 prior regimen containing rituximab, either alone or in
                       combination, and not be a candidate for hematopoietic SCT or BM transplant

                    -  B-cell CLL: Relapsed from or refractory to ≥ 2 prior lines of treatment, ≥ 1
                       of which must have contained rituximab

               -  Arm B: Relapsed from or refractory to ≥ 2 prior chemotherapy regimens with ≥ 1
                  regimen containing rituximab

               -  Arm C: Relapsed from or refractory to ≥ 2 prior chemotherapy regimens with ≥ 1
                  regimen containing rituximab or failed 1 prior rituximab-containing regimen and
                  unable to tolerate additional multiagent chemotherapy

               -  Arm D: Refractory to ≥ 1 regimen containing any anti-CD20-based therapy,
                  including salvage regimens and maintenance rituximab. Refractory subjects are
                  defined as any subject with less than a PR to any prior anti-CD20-based therapies
                  or progressed within 6 months after completing therapy with any anti-CD20-based
                  regimens, including maintenance rituximab. These subjects must not be eligible
                  for hematopoietic SCT or BM transplant

          7. Prior radiation therapy is allowed provided exposure does not exceed an area of 25% of
             marrow space and occurred ≥ 6 weeks prior to the first dose of MEDI-551 (Arm A only)

          8. Karnofsky performance status ≥ 70

          9. Life expectancy of ≥ 12 weeks

         10. Adequate hematologic function

             Arm A (except for CLL subjects with significant BM involvement by biopsy) must meet
             the following criteria:

               -  Hemoglobin ≥ 9 g/dL, (≥ 8 g/dL for subjects who are transfusion dependent)

               -  Absolute neutrophil count ≥ 1500/mm3

               -  Platelet count ≥ 75,000/mm3

             Arms B, C, and D must meet the following criteria:

               -  Hemoglobin ≥ 8 g/dL

               -  Absolute neutrophil count ≥ 1000/mm3

               -  Platelet count ≥ 75,000/mm3

               -  In the event of significant BM involvement, the above hematologic criteria will
                  not be required for enrollment eligibility

         11. Adequate organ function defined as follows:

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2 ×
                  institutional upper limit of normal (ULN)

               -  Bilirubin ≤ 1.5 × ULN except for subjects with documented Gilbert's disease, ≤
                  2.5 × ULN;

               -  Serum creatinine ≤ 1.5 mg/dL or a calculated creatinine clearance of ≥ 60 mL/min
                  as determined by the Cockcroft-Gault equation

         12. Female subjects of childbearing potential who are sexually active with a nonsterilized
             male partner must use highly effective contraception from screening and must agree to
             continue using such precautions for at least 180 days after the last dose of
             investigational product. Depending on the investigational product received, this
             period may be longer. Cessation of birth control after this point should be discussed
             with a responsible physician

               -  Females of childbearing potential are defined as those who are not surgically
                  sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete
                  hysterectomy) or those who are postmenopausal (defined as 12 months with no
                  menses without an alternative medical cause or follicle-stimulating
                  hormone/luteinizing hormone levels consistent with a menopausal state)

               -  A highly effective method of contraception is defined as one that results in a
                  low failure rate (ie, less than 1% per year) when used consistently and
                  correctly. Acceptable methods of contraception are described in Table 4.2.1-1.
                  Sustained abstinence is an acceptable practice; however, periodic abstinence, the
                  rhythm method, and the withdrawal method are not acceptable methods of
                  contraception

         13. Non-sterilized males who are sexually active with a female partner of childbearing
             potential must use a highly effective method of contraception (Table 4.2.1-1) from at
             least Day 1 through 90 days after the last dose of investigational product

         14. Negative serum beta human chorionic gonadotropin (βhCG) test (for women of
             childbearing potential only)

         15. Females or female partners not of childbearing potential must have been surgically
             sterilized or postmenopausal (as defined above in inclusion criterion #12). Sterilized
             males must be at least 1 year post vasectomy

        Exclusion Criteria:

          1. Any available standard line of therapy known to be life-prolonging or life-saving

          2. Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy
             for treatment of cancer

          3. History of allergy or reaction to any component of the MEDI-551 formulation

          4. Receipt of any chemotherapy or small molecule targeted therapy (such as imatinib or
             other tyrosine kinase inhibitors, and including any experimental therapies) or
             radiation therapy within 28 days or 5 half-lives, whichever is shorter, prior to the
             first dose of MEDI-551

          5. Receipt of any biological or immunological-based therapies (including experimental
             therapies) for leukemia, lymphoma, or myeloma (including, but not limited to, MAb
             therapy such as rituximab, or cancer vaccine therapies) within 28 days or 5
             half-lives, whichever is shorter, prior to the first dose of MEDI-551

          6. Previous therapy directed against CD19, such as MAbs or MAb conjugates

          7. Live or attenuated vaccines (other than experimental cancer vaccine therapy) within 28
             days prior to receiving the first dose of MEDI-551

          8. Evidence of significant active infection requiring antimicrobial, antifungal,
             antiparasitic, or antiviral therapy or for which other supportive care is given

          9. Autologous SCT within 12 weeks prior to study entry (Arms A and D only)

         10. Prior allogeneic SCT or organ transplant (Arms A and D only)

         11. Human immunodeficiency virus (HIV) positive serology or AIDS

         12. Active hepatitis B as defined by seropositivity for hepatitis B surface antigen or
             positive hepatitis B core antibody. Subjects with hepatitis C antibody will be
             eligible provided that they do not have elevated liver transaminases

         13. Ongoing ≥ Grade 2 toxicities from previous cancer therapies unless specifically
             allowed in the Inclusion/Exclusion criteria. Use of immunosuppressive medication other
             than steroids within 28 days before the first dose of MEDI-551

         14. Use of systemic steroids within 7 days before the first dose of MEDI-551 (inhaled and
             topical corticosteroids are permitted). Subjects may take replacement doses of
             steroids (defined as ≤ 30 mg/day hydrocortisone or the equivalent) if on a stable dose
             for at least 2 weeks prior to the first dose of MEDI-551. This does not include
             required steroid prophylaxis prior to the first infusion of MEDI-551

         15. Documented current central nervous system involvement by leukemia or lymphoma

         16. Pregnancy or lactation

         17. Previous medical history, or evidence, of an intercurrent illness that at the
             discretion of the principal investigator may compromise the safety of the subject in
             the study

         18. Clinically significant abnormality on electrocardiogram (ECG). The corrected QT
             interval (QTc, Fridericia) must be &lt; 470 milliseconds for men and &lt; 490 milliseconds
             for women (Must be confirmed by at least 2 additional 12-lead ECGs at least 2 minutes
             apart such that average manually over-read QTcF based on 3 ECGs exceeds stated
             thresholds)

         19. Any physical, social, or psychiatric condition that would prevent effective
             cooperation or participation in the study

         20. Concurrent enrollment in another clinical study, unless in a follow-up period or it is
             an observational study

         21. Employees of the clinical study site who are directly involved with the conduct of the
             study, or immediate family members of such individuals. These subjects may be treated
             at another site participating in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MedImmune LLC</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cona</city>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Albania</country>
    <country>France</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2009</study_first_submitted>
  <study_first_submitted_qc>September 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2009</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

